如何在低危骨髓增生异常综合征中使用罗特西普与促红细胞生成素刺激剂
贫血是骨髓增生异常综合征(MDS)最常见的血细胞减少,影响生活质量与发病率。促红细胞生成素刺激剂(ESA)是低危(LR)-MDS贫血的一线治疗;欧洲药品管理局(EMA)于2017年基于一项独特的随机3期试验及多项试验积累证据批准促红素α用于LR-MDS相关贫血。罗特西普是转化生长因子β(TGF-β)通路的配体陷阱,可促进晚期红系分化,在ESA失败后的MDS环形铁粒幼细胞(RS)及所有亚型MDS的ESA初治输血依赖患者中显示活性;由于近期也获批用于ESA初治LR-MDS,确定输血依赖前后最佳治疗流程变得关键。ESA与罗特西普作用机制不同,整合入治疗策略已可行,但需进一步证据以最大化疗效并改善患者结局。
要点
- ESA是低危MDS贫血的一线治疗,EMA于2017年批准促红素α用于LR-MDS相关贫血。
- 罗特西普为TGF-β通路配体陷阱,促进晚期红系分化,改善LR-MDS输血依赖性贫血。
- 罗特西普在ESA失败后的MDS-RS及所有亚型MDS的ESA初治输血依赖患者中显示活性。
核心结论
- ESA与罗特西普作用机制不同,整合入LR-MDS贫血治疗策略已可行,但需进一步证据以最大化疗效并改善患者结局。
研究设计与样本
- 综述,基于EMA于2017年批准促红素α所依据的一项独特随机3期试验及多项试验积累证据,讨论ESA与罗特西普在LR-MDS贫血中的使用。
主要发现
- 贫血是MDS最常见的血细胞减少,显著影响生活质量与发病率。
- 罗特西普是TGF-β通路的配体陷阱,该通路激活与MDS终末红系成熟受损相关;罗特西普促进晚期红系分化,改善LR-MDS输血依赖性贫血。
- 罗特西普在ESA失败后的MDS-RS及所有亚型MDS的ESA初治输血依赖患者中显示活性。
- 由于近期也获批用于ESA初治LR-MDS,确定输血依赖前后最佳治疗流程变得关键。
关键数值与推荐
- EMA于2017年批准促红素α用于LR-MDS相关贫血,依据为一项独特随机3期试验及多项试验积累证据。
- ESA为LR-MDS贫血的一线治疗。
- 罗特西普近期获批用于ESA初治LR-MDS。
临床怎么用
- ESA与罗特西普作用机制不同,整合入治疗策略已可行,但需进一步证据以最大化疗效并改善患者结局。
局限性
- ESA与罗特西普整合入治疗策略需要进一步证据以最大化疗效并改善患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis-stimulating agents (ESAs) are the first-line treatment for anaemia in lower risk (LR)-MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR-MDS-related anaemia in 2017, based on evidence from a unique randomized Phase 3 trial and accumulated evidence in many trials, providing support to an already widely utilized therapeutic option. Luspatercept, a more recently approved agent, is a ligand trap for transforming growth factor beta (TGF-β) pathway, whose activation is associated with impaired terminal erythroid maturation in MDS. Luspatercept facilitates late-stage erythroid differentiation, improving transfusion-dependent anaemia in LR-MDS, and has shown activity after ESA failure in MDS-ring sideroblasts (RS) and in all subtypes of MDS ESA naïve transfusion-dependent patients. Due to the recent approval of luspatercept also in ESA naïve LR-MDS, it has become crucial to determine the optimal treatment algorithm for anaemic LR-MDS, before and after transfusion dependence. ESAs and luspatercept are characterized by distinct mechanisms of action, and their integration into treatment strategies is already possible, but requires further evidence to maximize efficacy and improve patient outcomes.
引用
- Santini V, Consagra A. How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome. Br J Haematol. 2025. PMID: 40318055. doi:10.1111/bjh.20126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。